# Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

> **NCT05510063** · PHASE4 · COMPLETED · sponsor: **Samsung Bioepis Co., Ltd.** · enrollment: 371 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Humira (Adalimumab)
- **DRUG:** SB5 (Adalimumab Biosimilar)

## Key facts

- **NCT ID:** NCT05510063
- **Lead sponsor:** Samsung Bioepis Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-04
- **Primary completion:** 2023-04-04
- **Final completion:** 2023-05-04
- **Target enrollment:** 371 (ACTUAL)
- **Last updated:** 2023-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05510063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05510063, "Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT05510063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*